BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8241947)

  • 21. [Improvement of the anemia associated with multiple myeloma and renal dysfunction by recombinant human erythropoietin].
    Nakata H; Matsuzaki M; Shimamoto Y; Yamaguchi M
    Rinsho Ketsueki; 1990 Oct; 31(10):1752-3. PubMed ID: 2255069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.
    Cazzola M; Messinger D; Battistel V; Bron D; Cimino R; Enller-Ziegler L; Essers U; Greil R; Grossi A; Jäger G; LeMevel A; Najman A; Silingardi V; Spriano M; van Hoof A; Ehmer B
    Blood; 1995 Dec; 86(12):4446-53. PubMed ID: 8541533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.
    Nowrousian MR
    Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.
    Ludwig H; Sundal E; Pecherstorfer M; Leitgeb C; Bauernhofer T; Beinhauer A; Samonigg H; Kappeler AW; Fritz E
    Cancer; 1995 Dec; 76(11):2319-29. PubMed ID: 8635038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma.
    San Miguel JF; García-Sanz R
    Med Oncol; 1998 Aug; 15 Suppl 1():S29-34. PubMed ID: 9785334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.
    Rodríguez JN; Martino ML; Diéguez JC; Prados D
    Haematologica; 1998 Jul; 83(7):616-21. PubMed ID: 9718866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. rHuEPO and improved treatment outcomes: potential modes of action.
    Blackwell K; Gascón P; Sigounas G; Jolliffe L
    Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03).
    Machtay M; Pajak TF; Suntharalingam M; Shenouda G; Hershock D; Stripp DC; Cmelak AJ; Schulsinger A; Fu KK;
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1008-17. PubMed ID: 17716826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
    Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
    Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of treatment of anemia with erythropoietin in patients with multiple myeloma].
    Adam Z; Krahulová M; Spelda S; Vorlícek J; Hejlová N; Hájek R; Tomíska M
    Vnitr Lek; 1995 Nov; 41(11):767-72. PubMed ID: 8553596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Human recombinant erythropoietin in the treatment of the anemia of multiple myeloma].
    Valladares Ayerbes MJ; Valenzuela Claros JC; Reina Zoilo JJ; Ruiz Borrego M; Moreno Nogueira JA
    An Med Interna; 1997 Nov; 14(11):593-4. PubMed ID: 9445590
    [No Abstract]   [Full Text] [Related]  

  • 32. Therapy of anemia in patients with multiple myeloma.
    Adam Z; Krahulová M; Spelda S; Vorlícek J; Hejlová N; Hájek R; Tomíska M
    Acta Med Austriaca; 1995; 22(4):59-64. PubMed ID: 8835422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologic basis for the pharmacologic use of recombinant human erythropoietin in surgery and cancer treatment.
    Adamson JW; Spivak JL
    Surgery; 1994 Jan; 115(1):7-15. PubMed ID: 8284765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Erythropoietic protein supportive treatment in small cell lung cancer].
    Tamási L; Müller V; Magyar P; Losonczy G
    Magy Onkol; 2008 Mar; 52(1):43-6. PubMed ID: 18403296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. rHuEPO and treatment outcomes: the preclinical experience.
    Ludwig H
    Oncologist; 2004; 9 Suppl 5():48-54. PubMed ID: 15591422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoietin and chronic lymphocytic leukemia.
    Mauro FR; Gentile M; Foa R
    Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recombinant human erythropoietin in the treatment of anemic patients undergoing chemotherapy for cancer].
    Bösze P; Mayer A; Thurzó L; Kiss A; Rák K; Stumpf J
    Orv Hetil; 1995 Nov; 136(47):2567-72. PubMed ID: 8532322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
    Monnerat C; Leyvraz S
    Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.